Thrombocytopenia differential diagnosis: Difference between revisions
Line 16: | Line 16: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan=" | ! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
Line 25: | Line 25: | ||
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | | colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
! colspan=" | ! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
|- | |- | ||
Line 40: | Line 40: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
|- | |- | ||
Line 55: | Line 54: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 84: | Line 82: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 113: | Line 110: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 142: | Line 138: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 173: | Line 168: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 202: | Line 196: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 230: | Line 223: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 258: | Line 250: | ||
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ||
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 287: | Line 278: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 316: | Line 306: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 345: | Line 334: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 374: | Line 362: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 403: | Line 390: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Alport syndrome | ! align="center" style="background:#DCDCDC;" + |Alport syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 432: | Line 418: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 464: | Line 449: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 514: | Line 498: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
Line 531: | Line 514: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |Any | | align="center" style="background:#F5F5F5;" + |Any | ||
| align="center" style="background:#F5F5F5;" + |- | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |- | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |[[Bruise|Ecchymoses]] and | | align="center" style="background:#F5F5F5;" + |[[Bruise|Ecchymoses]] and | ||
[[petechia]] | [[petechia]] | ||
| align="center" style="background:#F5F5F5;" + | + [[Mucocutaneous zone|Mucocutaneous]] | | align="center" style="background:#F5F5F5;" + | + [[Mucocutaneous zone|Mucocutaneous]] | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |- | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |- | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |- | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |↓↓↓ | | align="center" style="background:#F5F5F5;" + |↓↓↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Large [[Platelet|platelets]], otherwise normal | ||
| align="center" style="background:#F5F5F5;" + |Nl | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |NA | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + |Spontaneous remission | | align="center" style="background:#F5F5F5;" + |Spontaneous remission | ||
|- | |- | ||
Line 557: | Line 539: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 586: | Line 567: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 616: | Line 596: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 665: | Line 644: | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 675: | Line 653: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 704: | Line 681: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 735: | Line 711: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 762: | Line 737: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 790: | Line 764: | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]] | ! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]] | ||
! align="center" style="background:#DCDCDC;" + |[[Malaria]] | ! align="center" style="background:#DCDCDC;" + |[[Malaria]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 819: | Line 792: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |[[Babesiosis]] | ! align="center" style="background:#DCDCDC;" + |[[Babesiosis]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 871: | Line 843: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
Line 888: | Line 859: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 917: | Line 887: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 945: | Line 914: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 974: | Line 942: | ||
| align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]] | | align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]] | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,002: | Line 969: | ||
! align="center" style="background:#DCDCDC;" + |[[Over-the-counter drug|OTC agents]] | ! align="center" style="background:#DCDCDC;" + |[[Over-the-counter drug|OTC agents]] | ||
! align="center" style="background:#DCDCDC;" + |[[Quinine]]-containing beverages | ! align="center" style="background:#DCDCDC;" + |[[Quinine]]-containing beverages | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,034: | Line 1,000: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,061: | Line 1,026: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,113: | Line 1,077: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
Line 1,124: | Line 1,087: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,153: | Line 1,115: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,182: | Line 1,143: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,211: | Line 1,171: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,241: | Line 1,200: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,267: | Line 1,225: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,296: | Line 1,253: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |HELLP syndrome | ! colspan="2" align="center" style="background:#DCDCDC;" + |HELLP syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 17:03, 15 August 2018
Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytopenia differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytopenia differential diagnosis |
Risk calculators and risk factors for Thrombocytopenia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farbod Zahedi Tajrishi, M.D.
Overview
Thrombocytopenia has a broad range of potential causes. While a good history and physical examination can be helpful to diagnose some of these causes such as drug-induced thrombocytopenia, they usually don't suffice and further evaluation is often needed. There are also some useful points that may guide the physician to an appropriate diagnosis. For example, asymptomatic, isolated thrombocytopenia most probably suggests ITP, while thrombocytopenia in critically ill, hospitalized patients is usually suggestive of iatrogenic causes (eg. dilution), platelet consumption, bone marrow suppression from infection/sepsis, or even drug-induced thrombocytopenia. One should consider however, that a wide variety of other conditions such as autoimmune disorders, nutrient deficiencies, thrombotic microangiopathies could all as well cause thrombocytopenia.
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age range | History | Symptoms | Signs | |||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||
Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | UA | ||||||||||||||||
Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Plt | HB | WBC | |||||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | + | |||||||||||||||||||||||||
Aplastic anemia | + | |||||||||||||||||||||||||||
Acute leukemia | + | |||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | + | |||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | + | ||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | + | |||||||||||||||||||||||||||
DIC | + | |||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | + | ||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Age range | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | UA | Imaging | Gold standard | Associated findings | |
Rheumatologic/autoimmune disorders | ITP |
|
+ | + | - | - | + | Any | - | - | Ecchymoses and | + Mucocutaneous | Nl | - | - | - | ↓↓↓ | Nl | Nl | Nl | Large platelets, otherwise normal | Nl | Nl | Nl | NA | Diagnosis of exclusion | Spontaneous remission | |
Systemic lupus erythematosus (SLE) | + | |||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | Autoantibody-mediated syndrome | + | ||||||||||||||||||||||||||
Felty's syndrome | Splenomegaly | + | ||||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | ↑ | ↑ | |||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | ||||||||||||||||||||||||||
Tick-borne infection | + | |||||||||||||||||||||||||||
Viral infections | HIV | An ITP-like condition called primary HIV-associated thrombocytopenia | + | + | + | |||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | |||||||||||||||||||||||||||
Parasitic infections | Malaria | |||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Age range | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | UA | Imaging | Gold standard | Associated findings | |
Medication/toxicity | Antibiotics/ | Occurrence of drug-dependent, platelet-reactive antibodies | + | + | ||||||||||||||||||||||||
Heparin-induced thrombocytopenia | Anti-heparin/PF4 antibody | + | ELISA | Early or delayed-onset | ||||||||||||||||||||||||
Cytotoxic chemotherapy | + | |||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | ||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||
GI | Chronic liver disease | + | ||||||||||||||||||||||||||
Portal hypertension | ||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Age range | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | UA | Imaging | Gold standard | Associated findings | |
Vascular | Giant capillary hemangioma | Platelet destruction | + | |||||||||||||||||||||||||
Aortic aneurysm | Platelet destruction | + | ||||||||||||||||||||||||||
Cardiopulmonary bypass | Platelet destruction | + | ||||||||||||||||||||||||||
Other | Alcohol | + | ||||||||||||||||||||||||||
Post-transfusion purpura | Immune mediated platelet destruction | + | ||||||||||||||||||||||||||
Gestational thrombocytopenia | ||||||||||||||||||||||||||||
HELLP syndrome |